Current Status of Oligometastatic Prostate Cancer: Risk Factors and Treatment Approaches
Journal Title: Üroonkoloji Bülteni - Year 2018, Vol 17, Issue 3
Abstract
Prostate cancer (PCa) is a common disease that causes significant mortality rates. The widespread use of more sophisticated imaging methods has led to the identification of oligometastatic PCa, which has a limited number of metastases. Local therapy (radical prostatectomy and/or radiotherapy) for the primary tumor and metastasis-directed therapies have been proposed. A number of retrospective analyses have been conducted in this patient group to determine the place of systemic treatment, which is still the recommended standard treatment for metastatic disease. These studies were based on the aims of improving survival, protecting the patient from the potential side effects of systemic therapy, and eliminating local prostate-related symptoms. Although the studies were retrospective in nature, a survival advantage has been demonstrated in patients receiving local treatment or metastasis-directed treatments. It has been also shown in these studies that local treatment has no effect, at least no detrimental effect, on non-oncologic outcomes. However, these studies have significant limitations, primarily their retrospective design, differences in definitions and end-points used, and patient selection biases. Nevertheless, these results are clinically valuable and can be utilized in practice in some special cases. This patient group needs comprehensive standardization and risk stratification. Determining the definition, staging, treatment, and which patients will benefit from local treatment is essential. With ongoing prospective studies, it is expected that these uncertainties will be resolved and there will be revolutionary changes in the treatment of oligometastatic PCa in the near future.
Authors and Affiliations
Fuat Kızılay
Keywords
Related Articles
- EP ID EP382526
- DOI 10.4274/uob.1088
- Views 83
- Downloads 0
Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report
Prostate cancer is one of the most common tumors in men. Docetaxel and prednisone treatment are accepted as standard therapy in castration-resistant prostate cancer patients. Docetaxel is a chemotherapeutic drug of the t...
University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Clinic of Urology, İzmir, Turkey
Granulomatous prostatitis, first described by Tanner and McDonald in 1943, is a histopathological diagnosis that includes mixed type inflammation with granulomas in the prostatic tissue. Granulomatous prostatitis compris...
Comparison of Lidocaine and Prilocaine Efficiencies in Periprostatic Nerve Block for Transrectal Prostate Biopsy: A Randomized Prospective Study
Objective: Periprostatic nerve block (PPNB) and intrarectal local anesthesia (IRLA) are two of the most commonly used methods for pain control in the transrectal ultrasonography (TRUS)-guided prostate needle biopsy proce...
Ablation Therapies in Small Renal Masses
Small renal masses are defined as renal neoplasms with the largest diameter less than 4 cm and the incidence of renal malignancies is increased with the widespread use of cross-sectional imaging methods. One of the optio...
Bladder Leiomyoma in Men: Report of Two Cases and Review of the Literatüre
Leiomyomas, which originate from smooth muscle cells, are considered as a benign mesenchymal neoplasm and rarely seen in the bladder. The clinical presentation of bladder leiomyoma might vary according to the size and lo...